We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00956501
Recruitment Status : Completed
First Posted : August 11, 2009
Last Update Posted : April 25, 2022
Information provided by (Responsible Party):
Wake Forest University Health Sciences

Brief Summary:
The purpose of this pilot study is to characterize changes in postural orientation and equilibrium in early diagnosed ALS patient. The investigators plan to cross validate the use of a standardized test of equilibrium (EquiTest, Computerized Dynamic Posturography - CDP) in early diagnosed ALS patients.

Condition or disease
Amyotrophic Lateral Sclerosis

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 35 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
Study Start Date : February 2009
Actual Primary Completion Date : February 2010
Actual Study Completion Date : February 2011

Primary Outcome Measures :
  1. SOT equilibrium scores on conditions 1-6. [ Time Frame: 9 monthes ]

Secondary Outcome Measures :
  1. MSS on conditions 1-6 Weight Symmetry Score on conditions 1-6 DGI score TUG score POMA-B score [ Time Frame: 9 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with Amyotrophic Lateral Sclerosis

Inclusion Criteria:

Inclusion Criteria for subjects with early ALS:

  • Probable or definite ALS according to World Federation of Neurology diagnostic criteria4.
  • Early stage ALS defined as presence of:

    1. Normal lower extremities muscle strength (≥ 4/5 in manual muscle strength or ≥ 80% in the computerized dynamometer quantitative muscle strength);
    2. ALSFRS score of ≥ than 30;
    3. FVC of ≥75% predicted;
    4. Ambulatory without the use of any assistive device.
  • 18 - 75 years of age.
  • Able to provide informed consent.

Inclusion Criteria for control subjects:

  • Healthy 18 - 75 years of age without significant medical condition as defined by the investigator.
  • Able to provide informed consent.
  • Not having any of the exclusion criteria listed below.

Exclusion Criteria:

  • Age < 18 or > 75 years.
  • History of falls (2 or more in the last year), history of fainting, history of cerebrovascular accident (CVA) or myocardial infarction (MI), history of lower limb joint replacement.
  • History of neuromuscular dysfunction "except diagnosis of ALS for individuals with ALS".
  • Post-traumatic, septic, inflammatory, or neuropathic arthritis.
  • Lower extremity injury/surgery that may effect balance.
  • Vestibular pathology (i.e., inner ear problems, vertigo, meniere's).
  • Peripheral neuropathy.
  • Parkinson's Disease.
  • Currently taking anti-convulsive medications (e.g., clonazepam, diazepam, lorazepam,phenytoin, zonegran, carbamazepine, depakote, gabapentin, lamotrigine, lamotrigine, oxcarbazepine, tiagabine, topiramate)
  • Diabetes Mellitus.
  • No history of neurological or medical condition that may interfere with balance as defined by investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00956501

Layout table for location information
United States, North Carolina
Carolinas ALS Clinical Research Center
Charlotte, North Carolina, United States, 28207
Sponsors and Collaborators
Wake Forest University Health Sciences
Layout table for investigator information
Principal Investigator: Mohammed Sanjak, PhD, PT, MBA Carolinas Healthcare Sysetm
Layout table for additonal information
Responsible Party: Wake Forest University Health Sciences
ClinicalTrials.gov Identifier: NCT00956501    
Other Study ID Numbers: IRB# 02-09-12B
First Posted: August 11, 2009    Key Record Dates
Last Update Posted: April 25, 2022
Last Verified: July 2013
Keywords provided by Wake Forest University Health Sciences:
Additional relevant MeSH terms:
Layout table for MeSH terms
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases